Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israel, Tel Aviv
Ido Wolf
34 years of experience
accreditations :
Clinic is certified :
Adenocarcinoma treatment cost in Israel typically involves a diagnostic phase with a PET-CT scan priced between $1,400 and $1,900, followed by specialized care. Primary surgical interventions such as a robotic da Vinci prostatectomy range from $24,600 to $38,500, while advanced options like HIPEC run from $61,200 to $95,900. Total expenses depend on the affected organ, cancer stage, and hospital type. Patients often find 30-50% savings compared to the US. Top destinations include Tel Aviv, Jerusalem, and Haifa.
Typical Adenocarcinoma Treatment Costs in Israel
Bookimed Expert Insight: Patients with complex gastrointestinal cases benefit from multidisciplinary teams at JCI-accredited centers like Sourasky. Specialists there, such as Dr. Ron Greenberg, integrate HIPEC with advanced surgery for a 90% oncology success rate. For those seeking private care, Assuta Medical Center allows patients to select their specific senior surgeon. Hadassah is ideal for cases requiring Nobel Prize-level research and AI-driven robotic technologies.
| Israel | Turkey | Austria | |
| Whipple surgery | from $38,500 | from $23,000 | from $45,000 |
| Robotic da Vinci prostatectomy | from $24,570 | from $17,000 | from $20,000 |
| Proton-beam therapy | from $48,000 | from $70,000 | from $80,000 |
| Lung cancer surgery | from $27,500 | from $17,000 | from $42,000 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $61,200 | from $22,500 | from $40,000 |
Dr. Pelles Sharon specializes in advanced adenocarcinoma treatments at Sourasky Medical Center, including HIPEC and immunotherapy.
Head of the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center – Dr. Merimsky specializes in complex sarcoma cases.
Dr. Sarid specializes in chemotherapy and radiotherapy with over 38 years of experience of oncology experience at Israel's leading Sourasky (Ichilov) Medical Center.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Adenocarcinoma treatment in Israel is exceptionally safe for international patients due to JCI-accredited facilities and highly specialized oncology teams. Israeli centers report a 90% average success rate for oncology. Specialists focus on precision protocols. They often correct up to 30% of outside diagnoses.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky serve over 1,500,000 patients every year. This massive patient volume creates a data-rich environment for refining treatment protocols. Our data shows that top clinics often include comprehensive histopathology revisions in their packages. This step is vital because it catches diagnostic errors before treatment begins.
Patient Consensus: Patients note the relief of having complex diagnostic reviews confirm their exact cancer type. Many emphasize that the coordinated support from dedicated international departments makes navigating the hospital system stress-free.
Adenocarcinoma success rates in Israel are among the highest globally. Statistics show an 80% recovery rate for early-stage cases. Major centers report 90% efficiency for advanced or metastatic treatments. Specific conditions like prostate adenocarcinoma show success rates exceeding 95% due to specialized protocols.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky prioritize histopathology revisions before treatment begins. Data shows that refined diagnostics often lead to more targeted protocols. For example, Dr. Almog Ben Yaacov at Sheba has performed over 200 HIPEC procedures. This high volume in specialized techniques typically correlates with the superior survival outcomes seen in Israeli gastric and colorectal cases.
Patient Consensus: Patients note that getting a second opinion from Israeli specialists is common for complex cases. They often feel more confident after fast consultations that clarify tumor genetics and staging.
Israel's leading oncology centers specialize in treating adenocarcinoma through high-precision surgery and targeted therapies. Facilities like Sheba Medical Center and Sourasky Medical Center provide access to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and robotic Da Vinci systems. JCI-accredited hospitals in Tel Aviv and Ramat Gan report success rates reaching 90% for oncology cases.
Bookimed Expert Insight: Israeli oncology centers demonstrate a high level of surgical sub-specialization that directly impacts patient outcomes. For instance, packages at Sheba Medical Center for HIPEC include extensive diagnostics like PET/CT and histopathology revisions. This intensive approach ensures treatment precision. While Sourasky Medical Center offers robotic surgery with doctors like Dr. Yossefovitz Ofer, who trained at Memorial Sloan Kettering, bringing elite techniques to local patients.
Patient Consensus: Patients highlight that Israeli centers offer faster enrollment in clinical trials compared to European options. Many note the benefit of getting full genomic sequencing before arrival to access mutation-specific therapies.
Adenocarcinoma diagnosis in Israel involves high-precision imaging and molecular profiling at JCI-accredited centers. Specialists use PET-CT and PET-MRI to detect metastases and determine TNM staging. Facilities like Sheba Medical Center and Sourasky Medical Center integrate genomic testing and liquid biopsies to create personalized oncology protocols.
Bookimed Expert Insight: Israeli oncology centers demonstrate a high diagnostic volume. Sourasky Medical Center treats over 400,000 patients annually. This massive data pool allows clinics to offer rapid turnaround. Some diagnostic packages at Sheba Medical Center include PET/CT and MRI in a single comprehensive screening. This typically helps international patients complete full staging within 3 to 5 days.
Patient Consensus: Patients note that getting genomic profiling and PSMA-PET scans early is vital. They emphasize that Israeli labs integrate these advanced tests seamlessly into the initial staging process.
Adenocarcinoma treatment in Israel involves cutting-edge surgical and systemic therapies tailored to tumor location and genetics. Patients access advanced options like robotic da Vinci surgery, HIPEC, and SIRT. Specialized centers like Sheba and Sourasky prioritize multidisciplinary care and clinical trials for complex cases.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky differentiate themselves through high surgical volumes and specialized training. For example, Dr. Almog Ben Yaacov has performed over 200 HIPEC procedures. This level of specialization often correlates with the 90% success rate reported by Sourasky for oncology treatments. Patients should note that while basic packages for robotic surgery start around $27,300, complex cases requiring HIPEC can range from $52,300 to $68,000 depending on the inclusion of diagnostics and hotel stays.
Patient Consensus: Patients emphasize the need for comprehensive tumor profiling, including genetic and PD-L1 testing, before finalizing a plan. Many note that while standard care is available, explicitly asking about clinical trials can reveal additional options at academic centers.
Patients treating adenocarcinoma in Israel typically stay for 14 to 21 days. Surgical discharge occurs within 3 to 5 days for routine cases. Complex procedures like HIPEC or Whipple surgery require approximately 14 days of hospitalization. Local recovery lasts 1 to 2 weeks before flying home safely.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba prioritize early mobility to prevent post-op complications. Their `Day 2` physiotherapy protocol specifically targets the respiratory and circulatory systems. This high-intensity approach often allows international patients to transition to hotel-based recovery faster than in European centers. For aggressive cancers, Sheba Medical Center packages even bundle post-discharge hotel stays. This ensures patients remain near their surgical team during the critical first week of outpatient healing.
Patient Consensus: Patients emphasize planning for at least 3 weeks in Israel to handle follow-up tests and imaging. Many suggest packing loose clothing and stool softeners to manage common post-surgical side effects in the local climate.
Israeli hospitals provide comprehensive interpreter services and logistical support for international patients through dedicated departments. Most JCI-accredited facilities offer multilingual staff and personal coordinators. These professionals manage medical translations, visa facilitation, and airport transfers to ensure seamless care for foreign arrivals.
Bookimed Expert Insight: Advanced treatment packages in Israel often bundle high-value logistics directly into the medical cost. For instance, the $27,300 robotic surgery package at Sourasky Medical Center includes clinic transfers. This integration reduces the stress of navigating Tel Aviv for patients undergoing complex oncology procedures.
Patient Consensus: Patients note that while many Israeli doctors speak fluent English, having a dedicated coordinator is essential for navigating hospital bureaucracy. Those visiting Sheba Medical Center often highlight the convenience of having translation and housing support bundled together.